The clinical evidence on drug efficacy and effectiveness is constantly expanding and it can be a challenge to keep track and visualize the clinical landscape. Certara’s CODEx and clinical trial outcomes databases change all of that.
CODEx is a smart combination of incredibly detailed databases and a state-of-the art exploratory tool to visualize the intricacies of literature data. CODEx provides not only a wealth of information, but also the resources to maximize the value of the information.
Below are the CODEx databases that we have curated for immunology. Don’t hesitate to contact us if you would like a demo or a price quote.
Ankylosing Spondylitis
Asthma
Atopic Dermatitis
Crohn's Disease
Cystic Fibrosis
Multiple Sclerosis
Sjorgen's Syndrome
Ulcerative Colitis
The COVID-19 Clinical Outcomes Database was developed to document clinical safety and efficacy information from studies investigating treatments and emerging interventions. It captures all important aspects of reference information, study design, patient population characteristics, randomized and concomitant treatments, statistical analyses and results.
The complete Quantify COVID-19 Clinical Outcomes Database contains summary level endpoint data from 55 studies reported in 50 references. The 5 most commonly reported efficacy endpoints are death (46 studies), critical disease (34 studies), hospitalization discharge (30 studies), hospitalization (28 studies), and lymphocytes (25 studies).
The CODEx Psoriasis Clinical Outcomes Database was developed to document clinical safety and efficacy information from studies investigating treatments and emerging interventions. It captures all important aspects of reference information, study design, patient population characteristics, randomized and concomitant treatments, statistical analyses and results.
The complete database contains summary level endpoint data from 185 studies reported in 390 references. The 5 most commonly reported efficacy and biomarker endpoints are PASI75 (171 studies), PASI score (156 studies), PASI90 (145 studies), physician global assessment <=1 (136 studies), and PASI50 (110 studies).
The CODEx Rheumatoid Arthritis database was developed to document clinical safety and efficacy information from studies investigating treatments and emerging interventions. It captures all important aspects of reference information, study design, patient population characteristics, randomized and concomitant treatments, statistical analyses and results.
The complete database contains summary level endpoint data from 305 studies reported in 647 references. The 5 most commonly reported efficacy and biomarker endpoints are ACR20 (273 studies), ACR50 (262 studies), swollen joint count (262 studies), HAQ (261 studies), and tender joint count (260 studies).